Cancel
John Sundy
Chief Medical Officer and Head of R&D
@
Seismic Therapeutic
05bw.aap2b@0f2fbz6r0.f8a
Sign up to see email
See Linkedin
Known information
- Has clinical privileges in rheumatology at the Duke-affiliated Durham VA Medical Center
- Completed his residency and fellowship training at Duke
- Is a fellow of the American College of Rheumatology, the American Academy of Allergy Asthma and Immunology, and the American College of Physicians
- Is an Adjunct Professor of Medicine at Duke University
- Has authored over 100 scientific publications
- Serves on the board of directors of CARRA, the Childhood Arthritis and Rheumatology Research Alliance
- Is a rheumatologist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry
- His research career has focused on developing novel therapies for patients with inflammatory and fibrotic diseases
- Was the Chief Medical Officer of Pandion Therapeutics prior to its acquisition by Merck for $1.85 billion
- Previously served as Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences
- Led Gilead's entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs including Jyselica, which is approved in Europe and Japan for rheumatoid arthritis and/or ulcerative colitis
- Was a tenured Associate Professor of Medicine at Duke University and Associate Professor at the Duke-National University of Singapore Graduate Medical School
- Served as Associate Director of the Duke Clinical Research Institute and Director of Duke's Global Proof of Concept Research Unit Network in the US, Singapore and India
- Instrumental in the Phase 1-3 development of Krystexxa which is approved for patients with refractory gout
- Received his undergraduate education from Bucknell University
- Received his medical and scientific education at Drexel University
About Seismic Therapeutic
Seismic Therapeutic is a biotech company using machine learning to develop biologics for autoimmune diseases, with a focus on novel enzyme and antibody therapeutics.
Report inaccurate information